ADIA Stock — Adia Nutrition Inc

Adia Nutrition Inc (ADIA)

Updated October 15, 2026.

ADIA is a Stock. Total return is -12.4% over the past 22.6 years, 976.3 points behind SPY at 963.9%.

Adia Med Inc is a clinical-stage regenerative medicine company offering stem cell therapies and regenerative medicine treatments targeting aesthetics, orthopedics, and autoimmune diseases, along with nutritional supplements and biologic products sold direct-to-consumer. As an early-stage biotech company, it does not currently have a dividend distribution profile. The company appeals to investors with higher risk tolerance seeking exposure to regenerative medicine development rather than current income.

ADIA performance versus SPY

Price and return data through 2026-10-15.

Total return is -12.4% over the past 22.6 years, 976.3 points behind SPY at 963.9%. Over the past year its total return — price change plus distributions reinvested — is 233.6%. Its deepest 1-year drawdown was 73.4%.

ADIA key facts

Asset type

Stock

Asset class

Equity

Inception date

03/23/2004

Distribution frequency

None

Last close

$0.14 (as of 2026-10-15)

Market cap

$13,226,098

Average volume

2000.0

Beta

-8.767

Payout ratio

0.0%

EPS

$0.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ADIA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 73.4%.

Who may consider ADIA — and who may not

It is a weaker fit for investors who need monthly cash flow (ADIA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ADIA

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions